Altered sphingolipid metabolism in patients with metastatic pancreatic cancer

Biomolecules

Volumn 3, Issue 3, 2013, Pages 435-448

  Jiang, Yixing ^a   DiVittore, Nicole A ^a   Young, Megan M ^b   Jia, Zhiliang ^c   Xie, Keping ^c   Ritty, Timothy M ^b   Kester, Mark ^a,b   Fox, Todd E ^b  

^a PENN STATE CANCER INSTITUTE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Ceramide; CXCL10; Lipidomics; Pancreatic cancer; Sphingolipids

Indexed keywords

CERAMIDE; CEREBROSIDE; CXCL11 CHEMOKINE; EOTAXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LONG CHAIN FATTY ACID; SPHINGOLIPID; SPHINGOMYELIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ARTICLE; BIOLOGICAL ACTIVITY; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEREGULATION; ENZYME METABOLISM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPID ANALYSIS; LYMPH NODE METASTASIS; MASS SPECTROMETRY; METABOLITE; PANCREAS CANCER; PANCREATITIS; PROTEIN EXPRESSION;

EID: 84905864269     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom3030435     Document Type: Article

References (36)

1. Tholey, R.; Sawicki, J.A.; Brody, J.R. Molecular-based and alternative therapies for pancreatic cancer: Looking "out of the box". Cancer J. 2012, 18, 665-673.
2. Pan, S.; Brentnall, T.A.; Kelly, K.; Chen, R. Tissue proteomics in pancreatic cancer study: Discovery, emerging technologies and challenges. Proteomics 2013, 13, 710-721.
3. Lopez-Casas, P.P.; Lopez-Fernandez, L.A. Gene-expression profiling in pancreatic cancer. Expert Rev. Mol. Diagn. 2010, 10, 591-601.
4. Ogretmen, B.; Hannun, Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer 2004, 4, 604-616.
5. Hannun, Y.A.; Obeid, L.M. Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat. Rev. Mol. Cell. Biol. 2008, 9, 139-150.
6. Ryland, L.K.; Fox, T.E.; Liu, X.; Loughran, T.P.; Kester, M. Dysregulation of sphingolipid metabolism in cancer. Cancer Biol. Ther. 2011, 11, 138-149.
7. Barth, B.M.; Cabot, M.C.; Kester, M. Ceramide-based therapeutics for the treatment of cancer. Anticancer Agents Med. Chem. 2011, 11, 911-919.
8. Furuya, H.; Shimizu, Y.; Kawamori, T. Sphingolipids in cancer. Cancer Metastasis Rev. 2011, 30, 567-576.
9. Futerman, A.H.; Hannun, Y.A. The complex life of simple sphingolipids. EMBO Rep. 2004, 5, 777-782.
10. Bose, R.; Verheij, M.; Haimovitz-Friedman, A.; Scotto, K.; Fuks, Z.; Kolesnick, R. Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals. Cell 1995, 82, 405-414.
11. Perry, D.K.; Carton, J.; Shah, A.K.; Meredith, F.; Uhlinger, D.J.; Hannun, Y.A. Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J. Biol. Chem. 2000, 275, 9078-9084.
12. Garcia-Barros, M.; Paris, F.; Cordon-Cardo, C.; Lyden, D.; Rafii, S.; Haimovitz-Friedman, A.; Fuks, Z.; Kolesnick, R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300, 1155-1159.
13. Fox, T.E.; Bewley, M.C.; Unrath, K.A.; Pedersen, M.M.; Anderson, R.E.; Jung, D.Y.; Jefferson, L.S.; Kim, J.K.; Bronson, S.K.; Flanagan, J.M.; et al. Circulating sphingolipid biomarkers in models of type 1 diabetes. J. Lipid Res. 2011, 52, 509-517.
14. Koybasi, S.; Senkal, C.E.; Sundararaj, K.; Spassieva, S.; Bielawski, J.; Osta, W.; Day, T.A.; Jiang, J.C.; Jazwinski, S.M.; Hannun, Y.A.; et al. Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J. Biol. Chem. 2004, 279, 44311-44319.
15. Karahatay, S.; Thomas, K.; Koybasi, S.; Senkal, C.E.; Elojeimy, S.; Liu, X.; Bielawski, J.; Day, T.A.; Gillespie, M.B.; Sinha, D.; et al. Clinical relevance of ceramide metabolism in the pathogenesis of human head and neck squamous cell carcinoma (HNSCC): Attenuation of C(18)-ceramide in HNSCC tumors correlates with lymphovascular invasion and nodal metastasis. Cancer Lett. 2007, 256, 101-111.
16. Schiffmann, S.; Sandner, J.; Birod, K.; Wobst, I.; Angioni, C.; Ruckhaberle, E.; Kaufmann, M.; Ackermann, H.; Lotsch, J.; Schmidt, H.; et al. Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis 2009, 30, 745-752.
17. Senkal, C.E.; Ponnusamy, S.; Bielawski, J.; Hannun, Y.A.; Ogretmen, B. Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways. FASEB J. 2010, 24, 296-308.
18. Hartmann, D.; Lucks, J.; Fuchs, S.; Schiffmann, S.; Schreiber, Y.; Ferreiros, N.; Merkens, J.; Marschalek, R.; Geisslinger, G.; Grosch, S. Long chain ceramides and very long chain ceramides have opposite effects on human breast and colon cancer cell growth. Int. J. Biochem. Cell. Biol. 2012, 44, 620-628.
19. Gouaze-Andersson, V.; Cabot, M.C. Glycosphingolipids and drug resistance. Biochim. Biophys. Acta 2006, 1758, 2096-2103.
20. Gouaze-Andersson, V.; Yu, J.Y.; Kreitenberg, A.J.; Bielawska, A.; Giuliano, A.E.; Cabot, M.C. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. Biochim. Biophys. Acta 2007, 1771, 1407-1417.
21. Couvelard, A.; Hu, J.; Steers, G.; O'Toole, D.; Sauvanet, A.; Belghiti, J.; Bedossa, P.; Gatter, K.; Ruszniewski, P.; Pezzella, F. Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors. Gastroenterology 2006, 131, 1597-1610.
22. Park, H.U.; Kim, J.W.; Kim, G.E.; Bae, H.I.; Crawley, S.C.; Yang, S.C.; Gum, J.R., Jr.; Batra, S.K.; Rousseau, K.; Swallow, D.M.; et al. Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia. Pancreas 2003, 26, e48-e54.
23. Pfeffer, F.; Koczan, D.; Adam, U.; Benz, S.; von Dobschuetz, E.; Prall, F.; Nizze, H.; Thiesen, H.J.; Hopt, U.T.; Lobler, M. Expression of connexin26 in islets of Langerhans is associated with impaired glucose tolerance in patients with pancreatic adenocarcinoma. Pancreas 2004, 29, 284-290.
24. Sato, N.; Fukushima, N.; Maitra, A.; Iacobuzio-Donahue, C.A.; van Heek, N.T.; Cameron, J.L.; Yeo, C.J.; Hruban, R.H.; Goggins, M. Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am. J. Pathol. 2004, 164, 903-914.
25. Hamanaka, Y.; Hamanaka, S.; Suzuki, M. Sialyl Lewis(a) ganglioside in pancreatic cancer tissue correlates with the serum CA 19-9 level. Pancreas 1996, 13, 160-165.
26. Saddoughi, S.A.; Song, P.; Ogretmen, B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem. 2008, 49, 413-440.
27. Nava, V.E.; Hobson, J.P.; Murthy, S.; Milstien, S.; Spiegel, S. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp. Cell. Res. 2002, 281, 115-127.
28. Van Brocklyn, J.; Letterle, C.; Snyder, P.; Prior, T. Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: Role of ERK MAP kinase and phosphatidylinositol 3-kinase beta. Cancer Lett. 2002, 181, 195-204.
29. Sarkar, S.; Maceyka, M.; Hait, N.C.; Paugh, S.W.; Sankala, H.; Milstien, S.; Spiegel, S. Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. FEBS Lett. 2005, 579, 5313-5317.
30. Ponnusamy, S.; Selvam, S.P.; Mehrotra, S.; Kawamori, T.; Snider, A.J.; Obeid, L.M.; Shao, Y.; Sabbadini, R.; Ogretmen, B. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol. Med. 2012, 4, 761-775.
31. Fox, T.E.; Bewley, M.C.; Unrath, K.A.; Pedersen, M.M.; Anderson, R.E.; Jung, D.Y.; Jefferson, L.S.; Kim, J.K.; Bronson, S.K.; Flanagan, J.M.; et al. Circulating sphingolipid biomarkers in models of type 1 diabetes. J. Lipid Res. 2011, 52, 509-517.
32. Deutschman, D.H.; Carstens, J.S.; Klepper, R.L.; Smith, W.S.; Page, M.T.; Young, T.R.; Gleason, L.A.; Nakajima, N.; Sabbadini, R.A. Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am. Heart J. 2003, 146, 62-68.
33. Long, J.S.; Fujiwara, Y.; Edwards, J.; Tannahill, C.L.; Tigyi, G.; Pyne, S.; Pyne, N.J. Sphingosine 1-phosphate receptor 4 uses HER2 (ERBB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells. J. Biol. Chem. 2010, 285, 35957-35966.
34. Shida, D.; Fang, X.; Kordula, T.; Takabe, K.; Lepine, S.; Alvarez, S.E.; Milstien, S.; Spiegel, S. Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res. 2008, 68, 6569-6577.
35. Doll, F.; Pfeilschifter, J.; Huwiler, A. The epidermal growth factor stimulates sphingosine kinase-1 expression and activity in the human mammary carcinoma cell line MCF7. Biochim. Biophys. Acta 2005, 1738, 72-81.
36. Evans, A.; Costello, E. The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front. Physiol. 2012, 3, 270.